Cas:22149-35-5 Kaempferol 3-O-gentiobioside manufacturer & supplier

Chemical Name:Kaempferol 3-O-gentiobioside

CAS.NO:22149-35-5

Synonyms:Kaempferol 3-O-gentiobioside;4H-1-Benzopyran-4-one, 3-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)-;5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside;Kaempferol 3-O-diglucoside

Molecular Formula:C₂₇H₃₀O₁₆

Molecular Weight:610.518

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:991.0±65.0 °C at 760 mmHg

Density:1.8±0.1 g/cm3

Index of Refraction:1.764

PSA:269.43000

Exact Mass:610.153381

LogP:-0.52

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Kaempferol 3-O-gentiobioside chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Kaempferol 3-O-diglucoside physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4H-1-Benzopyran-4-one, 3-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)- Use and application,5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside technical grade,usp/ep/jp grade.

Related News: “We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.” 1-ethyl-3-methyl-1-(5-oxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-urea manufacturers Cholesterol drug Crestor, blood thinner Brilinta and acid reflux med Nexium have all suffered as a result. Brilinta, for example, saw emerging markets sales drop 40% at constant currencies to $180 million in the first six months of 2021. pyrrolo[2,3-b]pyrrolizine suppliers Specifically, the EC has cleared Verquvo (vericiguat) to treat patients who are stabilised after a recent decompensation event requiring intravenous therapy. [Cd(μ3-croconate)0.5(μ4-croconate)0.5(anti-1,2-bis(4-pyridyl)ethane)0.5(gauche-1,2-bis(4-pyridyl)ethane)0.5] vendor & factory.